Month: March 2025

Wendel completes the acquisition of a controlling stake in Monroe Capital LLC, a transformational transaction in line with its strategic roadmap

Written by Customer Service on March 31, 2025. Posted in Mergers And Acquisitions.

Wendel completes the acquisition of a controlling stake in Monroe Capital LLC, a transformational transaction in line with its strategic roadmapWendel’s Asset Management platform now represents c.€34 billion1 of AuM in private assets and is expected to generate, on a full year basis, c.€160 million2 of Fee Related Earnings and c.€185 million of total pre-tax profit in 2025Wendel (MF-FP) today announced that it has completed the definitive partnership agreement including the acquisition, together with AXA IM Prime, of 75% of Monroe Capital LLC (“Monroe Capital” or “the Company”), and a sponsoring program of $800 million to accelerate Monroe Capital’s growth, and will invest in GP commitment for up to $200 million. As part of the initial transaction, Wendel has invested $1.133 billion to acquire 72% of Monroe Capital’s shares (from...

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other Business HighlightsThe company also completed the...

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2024 and summarized recent business highlights. “Our late stage brilaroxazine program has consistently shown what we believe to be robust broad-spectrum...

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue,...

Rekor Systems Reports Strong 2024 Financial Results Highlighted by Record Revenue and Significant Operational Improvements

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

2024 Financial Highlights: A Year of Significant Growth and EfficiencyRecord Gross Revenue: Achieved record annual gross revenue of $46.0 million, representing a 32% increase from $34.9 million in 2023. Fourth Quarter Results: Gross revenue reached an all-time quarterly high of $13.3 million in Q4 2024, marking a 20% increase compared to Q4 2023. Improved Adjusted EBITDA: Substantially narrowed Adjusted EBITDA loss from $6.7 million in Q4 2023 to $4.7 million in Q4 2024, underscoring enhanced operational efficiency.COLUMBIA, Md., March 31, 2025 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR), a global leader in roadway intelligence, today announced its financial results for the fiscal year that ended December 31, 2024. Throughout 2024, Rekor demonstrated substantial progress in efficiently scaling operations while consistently...

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

– Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – – Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® capsule – – Preclinical data of four incretin-based molecules underscores the RaniPill® platform’s potential to facilitate the oral delivery of a diverse array of obesity treatments – – Phase 1 study for RT-114 for the treatment of obesity, expected to initiate in mid-2025 – – Conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN JOSE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Aqua Metals Reports Milestone Advancements, Strategic Progress, and Sierra ARC Lithium Battery Recycling Campus Developments in 2024

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

Validated closed-loop battery recycling technology, built commercial partnerships, and revised economic model to better pursue funding and scale domestic battery mineral production RENO, Nev., March 31, 2025 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium battery recycling, today announced key achievements from 2024 and outlined progress for 2025 as the Company delivered critical technical milestones and high-purity material production through its proprietary Li AquaRefining™ process. In the past year, Aqua Metals delivered industry-first milestones, strengthened commercial partnerships and opportunities, and expanded its strategic vision to build a resilient, low-capex, and rapidly scalable platform for critical mineral recovery in the U.S. The Company’s innovative Li AquaRefining™...

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial – – Halneuron® CINP P2b study interim data readout is expected in Q4 2025 – – Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward – – Capital raise provides operational runway through Q1 2026 – ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024. “We have made considerable progress in advancing our flagship Halneuron® CINP Phase 2b study, with interim data expected...

Disclosure of Voting Rights in IDEX Biometrics to Chair, Morten Opstad – 31 March 2025

Written by Customer Service on March 31, 2025. Posted in Public Companies.

At the close of business on 31 March 2025, Morten Opstad, chair of the board of IDEX Biometrics, held the following voting rights in IDEX, for the extraordinary general meeting on 11 April 2025. Total 63,760,705 shares or 7.37% of the share capital and votes, including shares held by Mr. Opstad and close relations. Some of the proxies may include voting instructions.Contact personsMarianne Bøe, Head of Investor Relations, Tel.: +47 918 00186Kristian Flaten, CFO, Tel.: +47 950 92322E-mail: ir@idexbiometrics.comAbout IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary...

HOPSCOTCH GROUPE : Annual Results 2024

Written by Customer Service on March 31, 2025. Posted in Earnings Releases And Operating Results.

Press release Paris, March 31, 2025 17h35Annual Results Section HOPSCOTCH GROUPE2024 Annual Results An ambition : reaching €200 Million in Gross Margin by 2030 HOPSCOTCH (Euronext Growth FR0000065278), a communications consulting group and a key player in digital, public relations, and events, announces the publication of its annual accounts as of December 31, 2024. These accounts were approved by the Executive Board and validated by the Supervisory Board on March 31, 2025, along with the Group’s strategic vision for the next five years. A vision made possible by:A successful growth strategy: €104.8 million in Gross Margin, +12.8% compared to 2023; An organizational structure designed to create value: €9.2 million in Operating Profit, representing 8.7% of Gross Margin; A solid financial structure: €34.1 million in Shareholders’...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals